Overview

A Controlled Study of Solriamfetol for ADHD in Adults

Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
A double-blind, placebo controlled study of solriamfetol for adults age 18 to 65 with diagnosis of Attention Deficit Hyperactivity Disorder.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Massachusetts General Hospital